Interventions & Therapies

Effective management of congenital CMV involves a combination of antiviral treatments, supportive care, and long-term therapeutic services to address hearing, developmental, and medical needs.

1. Antiviral Therapy

• Ganciclovir and Valganciclovir
  These are the primary antiviral medications used to treat infants with symptomatic congenital CMV or those with asymptomatic cCMV with isolated hearing loss.

  • Intravenous (IV) Ganciclovir, for infants who are not well enough to take oral medication, this IV version typically given at 5–6 mg/kg twice daily for 6 weeks, followed by oral therapy for 6 months, has been shown to:

    • Prevent hearing deterioration at 12 months

    • Improve developmental outcomes, including fewer delays on the Denver developmental test at 6 and 12 months PubMed Central CDC

  • Oral Valganciclovir (a well-absorbed prodrug of ganciclovir, around 16–17 mg/kg twice daily) offers comparable effectiveness with fewer short-term side effects. Extended treatment durations (up to 6 months) improve both hearing and neurodevelopmental outcomes at 12–24 months. AAP Publications The Lancet

  • Treatment Timing & Duration

    • Ideally started within the first month of life; some benefit may still be seen if initiated up to 13 weeks.

    • For isolated persistent symptoms (e.g., hepatitis without CNS involvement), even a 6-week course may be beneficial.

    • Longer courses (6 months vs. 6 weeks) yield better long-term developmental outcomes, particularly in language for infants with symptomatic cCMV. The Lancet

• Safety Profile & Side Effects
  Close monitoring is essential due to potential side effects, including low blood counts (neutropenia), anemia, thrombocytopenia, transaminitis, and rare renal impairment. PubMed Central

2. Supportive & Symptom-Based Therapies

• Early Childhood Services

  • Regular audiology testing are needed, even for infants who initially pass newborn tests, as hearing loss may develop later. CDC 

  • Speech therapy, early intervention, and educational support help address developmental, communication, and motor delays that may emerge over time. In most states, infants with congenital CMV will automatically qualify for Early Intervention CDC CT Insider

• Management of Immediate Medical Concerns

  • Antivirals can also help alleviate complications such as thrombocytopenia, organ involvement (e.g., liver and spleen), hepatitis, and pneumonitis.  National CMV Foundation

3. Emerging & Specialty Treatments

• Other Antivirals

  • For CMV treatment beyond congenital context—such as in transplant recipients or immunocompromised children—drugs like foscarnet, maribavir, and letermovir may be used. However, these are not standard therapy for congenital CMV in infants, and include risks like nephrotoxicity or are currently approved in other contexts.
    Wikipedia+2Wikipedia+2

• Immunoglobulin Therapy

  • CMV-specific hyperimmune globulin (CMV-IGIV) is generally used in transplant settings, not routinely for congenital CMV.
    Wikipedia

4. Follow-Up & Long-Term Outcomes

• Ongoing Monitoring

  • Children—especially those with early CNS involvement or confirmed first-trimester infection—should be followed until at least 6 years of age. This ensures timely identification and management of evolving hearing, vision, developmental, or neurological issues. The Lancet